Abstract
These trends reflect a paradigm shift toward minimally invasive and multifactorial diagnostic approaches. Our findings underscore evolving priorities in NDs biomarker research and highlight the importance of multi-omics, artificial intelligence (AI), and interdisciplinary collaboration for translational discovery and clinical application.
Introduction
Neurodegenerative diseases (NDs), such as Alzheimer's (AD) and Parkinson's (PD), represent a significant and growing global health burden. While advancements in neuroimaging and genetics have deepened our understanding of these conditions, the lack of definitive, non-invasive diagnostic tools remains a critical bottleneck for early detection and the development of disease-modifying therapies. This paper presents a comprehensive bibliometric analysis of the research landscape for neural injury biomarkers, synthesizing over three decades of literature to identify historical trends and forecast future directions.
Methodology and Data Landscape
The researchers conducted a quantitative analysis using CiteSpace (v.6.2. R4) and the Bibliometrix R package. The study analyzed a dataset of 1,228 peer-reviewed articles and reviews extracted from the Web of Science (WOS) Core Collection, covering the period from 1991 to late 2024.
As shown in the bibliometric overview, the field has maintained a steady 7.39% average annual growth rate, with a total of 79,916 citations across the dataset. This growth reflects the increasing urgency and scientific focus on identifying reliable indicators of neuronal damage.
Key Insights: The Evolution of Biomarker Research
The analysis identifies a clear, event-driven evolution in the field, divided into three distinct phases:
- Validation Era (1991–2015): Research was heavily focused on the amyloid cascade hypothesis, relying on invasive cerebrospinal fluid (CSF) tests to detect Aβ42 and tau.
- Multimodal Integration (2015–2020): Spurred by the failure of several anti-amyloid clinical trials, the field pivoted toward integrating multiple types of biomarkers to capture the broader, complex pathology of neurodegeneration.
- Blood & Inflammation Era (2020–2024): The current era is defined by the explosion of blood-based biomarkers (such as plasma p-tau181) and a heightened focus on neuroinflammation. This shift was largely enabled by high-sensitivity assays like Single-Molecule Array (SIMOA), which can detect proteins at femtogram levels, making reliable blood-based screening viable.
Global Leaders and Collaboration
The United States dominates the research landscape, contributing 41.86% of total publications. Other major contributors include the United Kingdom (11.07%) and China (9.20%). Institutional hubs like the University of California System and Harvard University lead in volume and impact.
Keyword analysis reveals that while "tau" remains a central focal point, there is a surging interest in markers related to frontotemporal lobar degeneration (FTLD) and plasma-based diagnostics. The Journal of Alzheimer's Disease remains the leading publication venue for these findings.
Future Perspectives
The paper highlights two major frontiers for the next decade of research:
- Multi-omics Integration: Combining genomics, proteomics, and single-nucleus RNA sequencing to capture the full complexity of neurodegeneration and identify specific glial subpopulations linked to inflammatory profiles.
- AI and Machine Learning: Leveraging deep learning to handle high-dimensional datasets, such as combining polygenic risk scores with plasma p-tau and GFAP levels to accurately stratify patients for targeted clinical trials.
By bridging the gap between biomarker discovery and clinical application, these advancements aim to provide more accessible, accurate, and non-invasive diagnostic pathways for patients worldwide.
Summary updated